Biomarkers · Chemical
We have not added a physiological summary for this biomarker yet. Compare the commercial laboratory assays and population reference ranges below.
Check orderable catalog codes, specimen types, fasting requirements, and demographic reference ranges across laboratories.
Laboratory assay overview
Serial testing shows that increasing amounts of IgG anti-C1q predict renal flares in SLE patients. Elevated serum titers of anti-C1q antibodies tend to be associated with proliferative forms of lupus, glomerulonephritis and subendothelial deposits of immune complexes.
Labcorp test directory, test code 520147
Laboratory assay overview
This assay serves as a non-invasive aid for the diagnosis of active proliferative lupus nephritis (LN) and for monitoring disease activity. Autoantibodies to C1q (C1q Ab; IgG isotype) are detected in a number of autoimmune and infectious diseases but are best described in patients with systemic lupus erythematosus (SLE). Several studies suggest that C1q Ab plays a pathogenic role in the development of LN and that serum levels correlate with disease activity [1]. Moreover, C1q Ab results demonstrate fair sensitivity and specificity for active proliferative LN [2]. In addition, C1q Ab levels may begin to rise in advance of a renal flare and absence of C1q Ab suggests that a flare is unlikely [3]. References 1. Bock M, Heijnen I, Trendelenburg M. Anti-C1q antibodies as a follow-up marker in SLE patients. PLoS One. 2015;10(4):e0123572. doi:10.1371/journal.pone.0123572 2. Yin Y, Wu X, Shan G, et al. Diagnostic value of serum anti-C1q antibodies in patients with lupus nephritis: a meta-analysis. Lupus. 2012;21(10):1088-1097. doi:10.1177/0961203312451202 3. Fatemi A, Samadi G, Sayedbonakdar Z, et al. Anti-C1q antibody in patients with lupus nephritic flare: 18-month follow-up and a nested case-control study. Mod Rheumatol. 2016;26(2):233-239. doi:10.3109/14397595.2015.1074649
<26 RU/mL
Quest Diagnostics test directory, test code 34303
Laboratory assay overview
This profile is used to aid in monitoring treatment for Lupus patients.
Labcorp test directory, test code 505770
Laboratory assay overview
This profile is comprised of Anti-C1q Ab, Anti-Ribosomal P Ab, Anti-Cardiolipin Abs (IgG, IgA, IgM), Anti-Beta2 Glycoprotein I Abs (IgG, IgA, IgM) and Anti-PS/PT (Phosphatidylserine/Prothrombin) Complex Abs (IgG, IgM). It may be useful in assessing lupus patient prognosis including nephritis, neuropsychiatric, thrombotic and other cardiovascular risk.
Labcorp test directory, test code 520555
We compile every detail above directly from named laboratory directories and published clinical studies. Laboratories calculate standard reference intervals from the statistical distribution of tested populations for a specific assay method and demographic group, rather than setting universal optimal targets.
Always review your personal lab results with a licensed clinician, or track your lab history and health goals in Aumnivida.
Spotted an error? Email hello@biomarkerlens.com with the page URL and the primary source that corrects the entry.